{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-045123","form_type":"8-K","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.183078+00:00","generated_at":"2026-05-30T01:26:53.012323+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ProPhase Labs Q3 net revenue $3.1M (down 63% YoY); net loss $6.6M ($0.35/sh)","bullets":["Net revenue $3.1M vs $8.4M in Q3 2023; net loss $6.6M ($0.35/sh) vs $5.1M ($0.30/sh).","Pharmaloz Manufacturing hired ThinkEquity to explore sale; projects $15M+ revenue over next 12 months.","BE-Smart esophageal cancer test initiated partnership talks with two billion-dollar diagnostic firms.","Equivir trial completed; final stats expected by end-November; preliminary data encouraging.","Cash $1.1M at Sep 30; plans to eliminate ~$6M/year overhead; working capital $13.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-045123","json":"https://secwatch.observer/filing/0001493152-24-045123.json","markdown":"https://secwatch.observer/filing/0001493152-24-045123.md","text":"https://secwatch.observer/filing/0001493152-24-045123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000149315224045123/0001493152-24-045123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000149315224045123/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:26:53.012323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}